View
212
Download
0
Tags:
Embed Size (px)
Citation preview
design
11C-FLB457
11C-FLB457
11C-FLB457
11C-FLB457
11C-FLB457
11C-FLB457
perospirone
perospirone
perospirone
perospirone
perospirone
perospirone
Why?
In the Arakawa paper, where does the baseline (aka ‘control’) data come from?
From Vernaleken et al…
Design of healthy control study:
11C-raclopride
11C-raclopride 11C-raclopride
Baseline
11C-raclopride
perospirone
This is a “single dose” study – why?As opposed to _______________?
design
Ziprasodone
Ziprasodone
Ziprasodone
Ziprasodone
Ziprasodone
Ziprasodone
‘short’ ‘long’
11C-fallypride
11C-fallypride
11C-fallypride
11C-fallypride
11C-fallypride
11C-fallypride
Lower EC50 for putamen compared to other (extrastriatal) regions means lower receptor occupancy by the drug (ziprasodone) for a given plasma concentration.
Suggests that there is a discrepancy between single dose measurements of occupancy and ‘steady state dosing’
But what else could it be?
Perhaps: Chronic treatment with Zipras leads to upregulation of receptors and lower occup levels…
Healthy controlsWhy use 11C-raclopride here?
Dosimetry?
Repeated scans on same day?
Displaceability in striatum?
DIFFERENT STUDIES DONE AT DIFFERENT CENTERS
But to do microdose study, the drug company would have to give the chemical formula to the university PET center… so they could label it.